Cargando…
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
We quantified human epidermal growth factor receptor 2 (HER2) RNA and protein expression in 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) in situ hybridization (ISH) group 4 (HER2/centromeric probe 17 (CEP17) ratio <2.0, average HER2 copy number ≥4.0 and &...
Autores principales: | Gupta, Swati, Neumeister, Veronique, McGuire, John, Song, Yan S., Acs, Balazs, Ho, Kenneth, Weidler, Jodi, Wong, Wendy, Rhees, Brian, Bates, Michael, Rimm, David L., Bossuyt, Veerle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715641/ https://www.ncbi.nlm.nih.gov/pubmed/31482108 http://dx.doi.org/10.1038/s41523-019-0122-x |
Ejemplares similares
-
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022) -
Macrodissection prior to Closed System RT-qPCR is not necessary for Estrogen Receptor and HER2 Concordance with IHC/FISH in Breast Cancer
por: Gupta, Swati, et al.
Publicado: (2018) -
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020) -
Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
por: Wang, Bo, et al.
Publicado: (2019) -
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)